Two types of biomarker-dependent chemo-immunotherapy for pancreatic cancer?

Cornelis J M Melief

doi:10.1016/j.xcrm.2022.100788

Two types of biomarker-dependent chemo-immunotherapy for pancreatic cancer?

Cell Rep Med. 2022 Oct 18;3(10):100788. doi: 10.1016/j.xcrm.2022.100788.

Author

Cornelis J M Melief¹

Affiliation

¹ Leiden University Medical Center, Leiden, The Netherlands; ISA Pharmaceuticals, Leiden, The Netherlands. Electronic address: melief@isa-pharma.com.

Abstract

Padron et al.¹ studied the combination of chemotherapy (gemcitabine and nab-paclitaxel) with either an anti-PD1 (nivolumab) or an anti-CD40 (sotigalimab) antibody in metastatic pancreatic cancer. They showed clinical benefit in individuals with unique biomarkers for each treatment combination.

Publication types

Comment

MeSH terms

Antineoplastic Combined Chemotherapy Protocols / therapeutic use
Biomarkers
Humans
Immunotherapy
Nivolumab* / therapeutic use
Pancreatic Neoplasms* / drug therapy
Treatment Outcome

Substances

Nivolumab
Biomarkers